Effect of EBI3 on radiation-induced immunosuppression of cervical cancer HeLa cells by regulating Treg cells through PD-1/PD-L1 pathway

Tumor Biology

Volumn 39, Issue 3, 2017, Pages

  Zhang, Song An ^a   Niyazi, Hu Er Xi Dan ^a   Hong, Wen ^a   Tuluwengjiang, Gu Li Xian ^a   Zhang, Lei ^a   Zhang, Yang ^a   Su, Wei Peng ^a   Bao, Yong Xing ^a  

^a XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

cervical cancer; EBI3; immunosuppression; PD 1 PD L1 pathway; Treg cell

Indexed keywords

EPSTEIN BARR VIRUS INDUCED GENE 3 PROTEIN; GLYCOPROTEIN; PEROXIDASE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; STREPTAVIDIN; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; EBI3 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MINOR HISTOCOMPATIBILITY ANTIGEN; PDCD1 PROTEIN, HUMAN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DOWN REGULATION; ENZYME REGULATION; FEMALE; FLOW CYTOMETRY; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE PROLIFERATION; MTT ASSAY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; UTERINE CERVIX CANCER; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; HELA CELL LINE; HUMAN; IMMUNOLOGY; NEOPLASMS, EXPERIMENTAL; PATHOLOGY; RADIATION RESPONSE; REGULATORY T LYMPHOCYTE; UTERINE CERVICAL NEOPLASMS;

ANIMALS; ANTIGENS, CD274; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; IMMUNOPHENOTYPING; IMMUNOSUPPRESSION; INTERLEUKINS; MINOR HISTOCOMPATIBILITY ANTIGENS; NEOPLASMS, EXPERIMENTAL; PROGRAMMED CELL DEATH 1 RECEPTOR; RATS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; UTERINE CERVICAL NEOPLASMS;

EID: 85016924301     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1177/1010428317692237     Document Type: Article

References (37)

1. Du XL, Tao J, Sheng XG. Intensity-modulated radiation therapy for advanced cervical cancer: a comparison of dosimetric and clinical outcomes with conventional radiotherapy. Gynecol Oncol 2012; 125(1): 151–157.
2. Di J, Rutherford S, Chu C. Review of the cervical cancer burden and population-based cervical cancer screening in China. Asian Pac J Cancer Prev 2015; 16(17): 7401–7407.
3. Piersma SJ. Immunosuppressive tumor microenvironment in cervical cancer patients. Cancer Microenviron 2011; 4(3): 361–375.
4. Torres-Poveda K, Bahena-Roman M, Madrid-Gonzalez C. Role of IL-10 and TGF-β1 in local immunosuppression in HPV-associated cervical neoplasia. World J Clin Oncol 2014; 5(4): 753–763.
5. De Freitas AC, Gomes Leitao Mda C, Coimbra EC. Prospects of molecularly-targeted therapies for cervical cancer treatment. Curr Drug Targets 2015; 16(1): 77–91.
6. Zhao S, Yao DS, Chen JY. Aberrant expression of mir-20a and mir-203 in cervical cancer. Asian Pac J Cancer Prev 2013; 14(4): 2289–2293.
7. Vici P, Mariani L, Pizzuti L. Immunologic treatments for precancerous lesions and uterine cervical cancer. J Exp Clin Cancer Res 2014; 33: 29.
8. Tirotta E, Duncker P, Oak J. Epstein-Barr virus-induced gene 3 negatively regulates neuroinflammation and T cell activation following coronavirus-induced encephalomyelitis. J Neuroimmunol 2013; 254(1–2): 110–116.
9. Zheng R, Liu H, Song P. Epstein-Barr virus-induced gene 3 (EBI3) polymorphisms and expression are associated with susceptibility to pulmonary tuberculosis. Tuberculosis 2015; 95(4): 497–504.
10. Shinsuke N, Hiroshi I. Overexpression of Epstein-Barr virus-induced gene 3 protein (EBI3) in MRL/lpr mice suppresses their lupus nephritis by activating regulatory T cells. Autoimmunity 2013; 46(7): 446–454.
11. Wirtz S, Billmeier U, McHedlidze T. Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis. Gastroenterology 2011; 141(5): 1875–1886.
12. Gonin J, Larousserie F, Bastard C. Epstein-Barr virus-induced gene 3 (EBI3): a novel diagnosis marker in Burkitt lymphoma and diffuse large B-cell lymphoma. PLoS ONE 2011; 6(9): e24617.
13. Nishino R, Takano A, Oshita H. Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer. Clin Cancer Res 2011; 17(19): 6272–6286.
14. Hou YM, Dong J, Liu MY. Expression of Epstein-Barr virus-induced gene 3 in cervical cancer: association with clinicopathological parameters and prognosis. Oncol Lett 2016; 11(1): 330–334.
15. Fromowitz FB, Viola MV, Chao S. Ras p21 expression in the progression of breast cancer. Hum Pathol 1987; 18(12): 1268–1275.
16. Thaxton L, Waxman AG. Cervical cancer prevention: immunization and screening. Med Clin North Am 2015; 99(3): 469–477.
17. Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010; 40(7): 1830–1835.
18. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010; 11(1): 7–13.
19. Mori M, Benotmane MA, Tirone I. Transcriptional response to ionizing radiation in lymphocyte subsets. Cell Mol Life Sci 2005; 62(13): 1489–1501.
20. Everaert H, Hoorens A, Vanhove C. Prediction of response to neoadjuvant radiotherapy in patients with locally advanced rectal cancer by means of sequential 18FDG-PET. Int J Radiat Oncol Biol Phys 2011; 80(1): 91–96.
21. Larousserie F, Bardel E, Pflanz S. Analysis of interleukin-27 (EBI3/p28) expression in Epstein-Barr virus- and human T-cell leukemia virus type 1-associated lymphomas: heterogeneous expression of EBI3 subunit by tumoral cells. Am J Pathol 2005; 166(4): 1217–1228.
22. Pilones KA, Vanpouille-Box C, Demaria S. Combination of radiotherapy and immune checkpoint inhibitors. Semin Radiat Oncol 2015; 25(1): 28–33.
23. Zhang Y, Wang L, Li Y. Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma. Onco Targets Ther 2014; 7: 567–573.
24. + T cells. Sci Transl Med 2013; 5(200): 200ra116.
25. Mu CY, Huang JA, Chen Y. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011; 28(3): 682–688.
26. Yamamoto R, Nishikori M, Kitawaki T. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008; 111(6): 3220–3224.
27. Thompson RH, Dong H, Lohse CM. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007; 13(6): 1757–1761.
28. Hamanishi J, Mandai M, Iwasaki M. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007; 104(9): 3360–3365.
29. Dovedi SJ, Adlard AL, Lipowska-Bhalla G. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 2014; 74(19): 5458–5468.
30. Bowers NL, Helton ES, Huijbregts RP. Immune suppression by neutrophils in HIV-1 infection: role of PD-L1/PD-1 pathway. PLoS Pathog 2014; 10(3): e1003993.
31. Franceschini D, Paroli M, Francavilla V. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest 2009; 119(3): 551–564.
32. Barthlott T, Moncrieffe H, Veldhoen M. CD25+ CD4+ T cells compete with naive CD4+ T cells for IL-2 and exploit it for the induction of IL-10 production. Int Immunol 2005; 17(3): 279–288.
33. De la Rosa M, Rutz S, Dorninger H. Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur J Immunol 2004; 34(9): 2480–2488.
34. Scheffold A, Huhn J, Hofer T. Regulation of CD4+CD25+ regulatory T cell activity: it takes (IL-) two to tango. Eur J Immunol 2005; 35(5): 1336–1341.
35. Keir ME, Butte MJ, Freeman GJ. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677–704.
36. Parry RV, Chemnitz JM, Frauwirth KA. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005; 25(21): 9543–9553.
37. Taube JM, Young GD, McMiller TL. Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade. Clin Cancer Res 2015; 21(17): 3969–3976.